安罗替尼联合阿美替尼治疗晚期非小细胞肺癌患者的疗效及对血管生成调节因子和细胞免疫水平的影响OA
Efficacy of Anlotinib Combined with Almonertinib in the Treatment of Advanced Non-Small Cell Lung Cancer and its Effects on Angiogenesis Regulators and Cellular Immunity
目的:探讨安罗替尼联合阿美替尼治疗晚期非小细胞肺癌(NSCLC)的疗效及对患者血管生成调节因子及细胞免疫水平的影响.方法:回顾性选取2022 年4月～2025 年4月某院收治的 92 例晚期 NSCLC 患者作为研究对象,根据治疗方案不同分为对照组(阿美替尼单药治疗)和研究组(安罗替尼联合阿美替尼治疗),每组46 例.比较两组患者血管生成因子及细胞免疫相关指标变化、临床疗效及不良反应发生情况.结果:治疗后,两组患者血管内皮生长因子(VEGF)、碱性成纤维细胞生长因子(bFGF)水平、转化生长因子-β(TGF-β)、CD8+水平均降低,且研究组低于对照组(P＜0.05);γ干扰素(IFN-γ)、肿瘤坏死因子-α(TNF-α)、CD4+、CD4+/CD8+均升高,且研究组高于对照组(P＜0.05).研究组客观缓解率(ORR)、疾病控制率(DCR)均高于对照组(71.74%vs 45.65%,86.96%vs 69.57%,P＜0.05);不良反应总发生率低于对照组(28.26%vs 52.17%,P＜0.05).结论:安罗替尼联合阿美替尼治疗晚期NSCLC患者能够提升抗肿瘤疗效,有效抑制新生血管形成,改善患者细胞免疫状态,且安全性良好.
Objective:To investigate the efficacy of anlotinib combined with almonertinib in the treatment of advanced non-small cell lung cancer(NSCLC),and its effects on angiogenesis regulators and cellular immunity.Methods:A total of 92 patients with advanced NSCLC admitted to our hospital from April 2022 to April 2025 were retrospectively enrolled and divided into control group(almonertinib monotherapy)and study group(anlotinib combined with almonertinib)according to treatment regimens,with 46 cases in each group.Angiogenesis factors,cellular immunity-related indexes,clinical efficacy and adverse reactions were compared between the two groups.Results:After treatment,the levels of vascular endothelial growth factor(VEGF),basic fibroblast growth factor(bFGF),transforming growth factor-β(TGF-β)and CD8+in the study group were significantly lower than those in the control group(P<0.05).The levels of interferon-γ(IFN-γ),tumor necrosis factor-α(TNF-α),CD4+and CD4+/CD8+ratio were significantly higher in the study group than those in the control group(P<0.05).The objective remission rate(ORR)and disease control rate(DCR)in the study group were significantly higher than those in the control group(71.74%vs 45.65%,86.96%vs 69.57%,P<0.05),while the total incidence of adverse reactions was significantly lower(28.26%vs 52.17%,P<0.05).Conclusion:Anlotinib combined with almonertinib can effectively improve the anti-tumor efficacy,inhibit angiogenesis,improve cellular immune status and show better safety in patients with advanced NSCLC.
申威;孟祥丽;谢晋玲;王瑾;杨珊珊
河南医药大学第一附属医院肿瘤内科,新乡 453100河南医药大学第一附属医院肿瘤内科,新乡 453100河南医药大学第一附属医院肿瘤内科,新乡 453100河南医药大学第一附属医院肿瘤内科,新乡 453100河南医药大学第一附属医院肿瘤内科,新乡 453100
医药卫生
安罗替尼阿美替尼非小细胞肺癌血管内皮生长因子细胞免疫
anlotinibalmonertinibnon-small cell lung cancervascular endothelial growth factorcellular immunity
《中国合理用药探索》 2026 (4)
15-20,6
河南省医学科技攻关计划项目(LHGJ20220624)
评论